AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9754454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10695381 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline concentration in blood serum
Number of subjects: 9
Study 10695381 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone concentration in blood serum
Number of subjects: 9
Study 2223154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oral bestatin treatment (30 mg daily for at least 1 year)
Number of subjects: 194
Study 2223154 — intervention group
Group type: COMPARATOR
Intervention: No bestatin (Control)
Number of subjects: 194
Study 631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (dialyzed on Mondays and Thursdays)
Number of subjects: 21
Study 631993 — intervention group
Group type: COMPARATOR
Intervention: Group B (dialyzed on Tuesdays and Fridays)
Number of subjects: 21
Study 31119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10 mg/160 mg + rosuvastatin 20 mg
Number of subjects: 57
Study 31119689 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 57
Study 27774609 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminder
Number of subjects: 0
Study 27774609 — intervention group
Group type: COMPARATOR
Intervention: Text message reminder
Number of subjects: 0
Study 27774609 — intervention group
Group type: COMPARATOR
Intervention: Letter reminder
Number of subjects: 0
Study 25804297 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated exercise intervention (usual care plus exercise support)
Number of subjects: 94
Study 25804297 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 94
Study 23422495 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3-8 ng/mL
Number of subjects: 833
Study 23422495 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 6-12 ng/mL
Number of subjects: 833
Study 23422495 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) 1.44 g per day
Number of subjects: 833
Study 22159930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 64
Study 22159930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19767606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 151
Study 19767606 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 151
Study 19767606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 151
Study 17182126 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF) treatment started within 24 hours after PCI.
Number of subjects: 40
Study 17182126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G‐CSF treatment).
Number of subjects: 40
Study 14996877 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (treatment group)
Number of subjects: 54
Study 14996877 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 54
Study 11323510 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen-section analysis
Number of subjects: 61
Study 11323510 — intervention group
Group type: COMPARATOR
Intervention: Non-frozen-section analysis
Number of subjects: 61
Study 9643615 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 15
Study 9643615 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin pretreatment
Number of subjects: 15
Study 9643615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 15
Study 9643615 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 15
Study 7943585 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping
Number of subjects: 156
Study 7943585 — intervention group
Group type: COMPARATOR
Intervention: High ligation combined with sclerotherapy
Number of subjects: 156
Study 2816806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter
Number of subjects: 6
Study 2816806 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 6
Study 31546738 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic indoor air monitoring and 24 h ambulatory monitoring of peripheral and central blood pressure, measures of central hemodynamic indices, standardized questionnaires, 24 h time-activity diary, clinic-based health assessment including blood and urine biomarkers for lipid and glucose profiles, renal function measures, central pulse wave and pulse wave velocity analysis.
Number of subjects: 111
Study 28454836 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (150 mg once daily)
Number of subjects: 0
Study 28454836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25942666 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Cream (moisturizer group)
Number of subjects: 45
Study 25942666 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare Treatment
Number of subjects: 45
Study 25942666 — intervention group
Group type: COMPARATOR
Intervention: Control group (cleanser only)
Number of subjects: 45
Study 22804902 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made thumb splint
Number of subjects: 35
Study 22804902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated thumb splint
Number of subjects: 35
Study 22804902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no splint)
Number of subjects: 35
Study 21477419 — intervention group
Group type: EXPERIMENTAL
Intervention: mebeverine hydrochloride plus CBT
Number of subjects: 149
Study 21477419 — intervention group
Group type: COMPARATOR
Intervention: mebeverine hydrochloride alone
Number of subjects: 149
Study 19210159 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 7797
Study 19210159 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 7797
Study 19210159 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 7797
Study 19210159 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 7797
Study 19210159 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 7797
Study 19210159 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 7797
Study 16838234 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4.5 g every 6 h)
Number of subjects: 528
Study 16838234 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (2 g every 8 h)
Number of subjects: 528
Study 12684731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg)
Number of subjects: 20
Study 12684731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10851204 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3610
Study 10851204 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 3610
Study 10851204 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 3610
Study 9366936 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 24
Study 9366936 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 24
Study 8258085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous cranial electrical stimulation with Limoge currents
Number of subjects: 120
Study 8258085 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine administration
Number of subjects: 120
Study 3884083 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy at a mean of 6.9 days after emergency admission
Number of subjects: 55
Study 3884083 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary tract investigations during the first week following admission
Number of subjects: 55
Study 31446217 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms (especially asociality and avolition)
Number of subjects: 73
Study 31446217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarker interleukin-2
Number of subjects: 73
Study 31446217 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous functioning and baseline cognitive performance in attention and vigilance
Number of subjects: 73
Study 29909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/d)
Number of subjects: 118
Study 29909285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 29909285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118
Study 26927363 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-site stimulation (left dorsolateral prefrontal stimulation, 1000 pulses, 20 Hz plus left and right temporoparietal stimulation, 1000 pulses each, 1 Hz)
Number of subjects: 49
Study 26927363 — intervention group
Group type: COMPARATOR
Intervention: Single-site stimulation (left temporoparietal stimulation, 3000 pulses, 1 Hz)
Number of subjects: 49
Study 25406842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Education Unit (DEU) clinical model
Number of subjects: 0
Study 25406842 — intervention group
Group type: COMPARATOR
Intervention: Practice partners' feedback
Number of subjects: 0
Study 22724115 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive AdheSE (AS)
Number of subjects: 50
Study 22724115 — intervention group
Group type: COMPARATOR
Intervention: Two-step etch-and-rinse adhesive Excite (EX)
Number of subjects: 50
Study 22724115 — intervention group
Group type: EXPERIMENTAL
Intervention: SEM analysis
Number of subjects: 50
Study 20096379 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvey‐Bradshaw Index
Number of subjects: 1000
Study 18724188 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban HIV/STD Risk Reduction Intervention (treatment)
Number of subjects: 535
Study 18724188 — intervention group
Group type: COMPARATOR
Intervention: Eban Health Promotion Intervention (control)
Number of subjects: 535
Study 15862509 — intervention group
Group type: EXPERIMENTAL
Intervention: RayGel (reduced glutathione and anthocyanins)
Number of subjects: 30
Study 15862509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12434307 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% gel forming solution (TXE)
Number of subjects: 32
Study 12434307 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% gel forming solution (TXG)
Number of subjects: 32
Study 12434307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TXE and TXG
Number of subjects: 32
Study 10483663 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing distance from the stair
Number of subjects: 20
Study 10483663 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair heights representing 83% and 93% of each group's mean leg length
Number of subjects: 20
Study 8960832 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CPII) for 12 months
Number of subjects: 18
Study 8960832 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 18
Study 2022266 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine (2.5 mg)
Number of subjects: 8
Study 2022266 — intervention group
Group type: COMPARATOR
Intervention: Oral bromocriptine (2.5 mg)
Number of subjects: 8
Study 6350743 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs ordered by physicians
Number of subjects: 2018
Study 6350743 — intervention group
Group type: COMPARATOR
Intervention: Chest radiographs not ordered by physicians
Number of subjects: 2018
Study 25555626 — intervention group
Group type: EXPERIMENTAL
Intervention: Book intervention (provision of a booklet with evidence-based information)
Number of subjects: 52075
Study 25555626 — intervention group
Group type: EXPERIMENTAL
Intervention: School-level interventions (book and/or feedback of names of children with high levels of ADHD symptoms)
Number of subjects: 52075
Study 25555626 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline inattention
Number of subjects: 52075
Study 25555626 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline impulsiveness
Number of subjects: 52075
Study 30601979 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week health program
Number of subjects: 229
Study 30601979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health program)
Number of subjects: 229
Study 28577671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + prasugrel
Number of subjects: 3539
Study 28577671 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + clopidogrel
Number of subjects: 3539
Study 28577671 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in patients with DM
Number of subjects: 3539
Study 28577671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel vs. clopidogrel
Number of subjects: 3539
Study 28577671 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment among DM patients
Number of subjects: 3539
Study 26096546 — intervention group
Group type: EXPERIMENTAL
Intervention: Real feedback group (rFB, n=13)
Number of subjects: 38
Study 26096546 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoke feedback group (yFB, n=13)
Number of subjects: 38
Study 26096546 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (noFB, n=12)
Number of subjects: 38
Study 25028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning Exercises in Assisted Living (REAL)
Number of subjects: 13
Study 25028542 — intervention group
Group type: COMPARATOR
Intervention: Attention control (vitamin education)
Number of subjects: 13
Study 25028542 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 13
Study 22005107 — intervention group
Group type: EXPERIMENTAL
Intervention: ELTGOL (slow expiration with glottis opened in lateral posture)
Number of subjects: 12
Study 22005107 — intervention group
Group type: COMPARATOR
Intervention: Control (ventilatory scintigraphy measurements only)
Number of subjects: 12
Study 18836778 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-flow vacuum-free bottle system (CFVFB)
Number of subjects: 30
Study 18836778 — intervention group
Group type: COMPARATOR
Intervention: Standard bottle (SB)
Number of subjects: 30
Study 17900394 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. topotecan
Number of subjects: 211
Study 17900394 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and vincristine
Number of subjects: 211
Study 15221507 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine 3 g/day for 7 weeks
Number of subjects: 30
Study 15221507 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 weeks
Number of subjects: 30
Study 12563929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fraxiparine) administered subcutaneously at 41 IU/kg.day for 3 days, then 62 IU/kg.day from day 4 to day 10.
Number of subjects: 46
Study 12563929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 46
Study 9849109 — intervention group
Group type: EXPERIMENTAL
Intervention: Action training
Number of subjects: 2
Study 9849109 — intervention group
Group type: COMPARATOR
Intervention: Concept training
Number of subjects: 2
Study 7912946 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil 0.4 mg kg‐1 i.v.
Number of subjects: 20
Study 7912946 — intervention group
Group type: COMPARATOR
Intervention: clonidine 2.5 micrograms kg‐1 i.v.
Number of subjects: 20
Study 2465748 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg mixed with decaffeinated coffee)
Number of subjects: 50
Study 2465748 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated drink alone
Number of subjects: 50
Study 29745711 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional segregation condition (large emotional differences between black vs. white subgroups)
Number of subjects: 12
Study 29745711 — intervention group
Group type: COMPARATOR
Intervention: Control condition (small emotional differences between black vs. white subgroups)
Number of subjects: 12
Study 28121670 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI only
Number of subjects: 0
Study 28121670 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-containing
Number of subjects: 0
Study 28121670 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor containing
Number of subjects: 0
Study 28121670 — intervention group
Group type: COMPARATOR
Intervention: CTX use
Number of subjects: 0
Study 28121670 — intervention group
Group type: COMPARATOR
Intervention: Placebo use
Number of subjects: 0
Study 26192006 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 1181
Study 26192006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean caffeinated coffee intake
Number of subjects: 1181
Study 26192006 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 1181
Study 26192006 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1495741
Number of subjects: 1181
Study 24288494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (20 sessions, every other day, 20 minutes each session)
Number of subjects: 0
Study 24288494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21343579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (15 mg/d)
Number of subjects: 243
Study 21343579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 18642021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic AcrySof IOL (group 1)
Number of subjects: 60
Study 18642021 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic Akreos adapt IOL (group 2)
Number of subjects: 60
Study 18642021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16392026 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 4806
Study 16392026 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 4806
Study 16392026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4806
Study 15164191 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg slow-release valproic acid (VPA)
Number of subjects: 20
Study 15164191 — intervention group
Group type: COMPARATOR
Intervention: 200 mg slow-release levodopa (LD) + 50 mg benserazid
Number of subjects: 20
Study 11152791 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of alar ligaments (coronal T1‐ and T2‐weighted and transverse T1‐weighted)
Number of subjects: 50
Study 11152791 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of craniocervical junction (CCJ) and C1-C2 joints
Number of subjects: 50
Study 11152791 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of C1-C2 joint
Number of subjects: 50
Study 11152791 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of CCJ and C1-C2 joints
Number of subjects: 50
Study 9258848 — intervention group
Group type: EXPERIMENTAL
Intervention: Long jumpers
Number of subjects: 0
Study 9258848 — intervention group
Group type: COMPARATOR
Intervention: Sprinting task
Number of subjects: 0
Study 9258848 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled jumpers
Number of subjects: 0
Study 9258848 — intervention group
Group type: EXPERIMENTAL
Intervention: Unskilled jumpers
Number of subjects: 0
Study 8387933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 12
Study 8387933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 12
Study 8387933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8387933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) with spacer
Number of subjects: 12
Study 8387933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) with spacer
Number of subjects: 12
Study 3311237 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2)
Number of subjects: 16
Study 3311237 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin (360 mg/m2)
Number of subjects: 16
Study 3311237 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (not administered in this trial, but mentioned for comparison)
Number of subjects: 16
Study 29178492 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated aluminum
Number of subjects: 0
Study 29178492 — intervention group
Group type: COMPARATOR
Intervention: Aluminum
Number of subjects: 0
Study 29178492 — intervention group
Group type: COMPARATOR
Intervention: Opal
Number of subjects: 0
Study 29178492 — intervention group
Group type: COMPARATOR
Intervention: Ground glass diffusers
Number of subjects: 0
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of seropositivity
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 1 or more comorbidities including autoimmune disorders
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic hyperplasia
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score classification
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity
Number of subjects: 101
Study 27031125 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under receiver operating characteristic curve
Number of subjects: 101
Study 25226827 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.5 g/KgBW/day)
Number of subjects: 6
Study 25226827 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous protein supplement (0.5 g/KgBW/day)
Number of subjects: 6
Study 23292928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 317
Study 23292928 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 317
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 24 weeks
Number of subjects: 140